Biotech Values

[caravon]

Regarding to Gild HCV franchise sale and earning. IMO,
- Gild share prices have already incorporated future HCV sale and earnings
- Wells, Goldman, and Credit Swisse project/speculate that Gild HCV sale will be somewhat flat (I will not argue about this)
- Assuming that ABBV/Enta HCV combo will be approved by this year end, this sale will come out from the projected potential Gild sale. Therefore, Wells, Goldman, and Credit Swisse somehow ignore an effect of ABBV/Enta HCV sale on Gild HCV franchise. In other word, Wells, Goldman, and Credit Swisse are assuming that ABBV/Enta HCV sale will be a failure. (Here comes my disagreement.)